BioXcel Therapeutics (BTAI) Cost of Revenue (2022 - 2025)
Historic Cost of Revenue for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $11000.0.
- BioXcel Therapeutics' Cost of Revenue fell 9905.98% to $11000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $964000.0, marking a year-over-year decrease of 5241.86%. This contributed to the annual value of $2.1 million for FY2024, which is 7007.94% up from last year.
- Latest data reveals that BioXcel Therapeutics reported Cost of Revenue of $11000.0 as of Q3 2025, which was down 9905.98% from $107000.0 recorded in Q2 2025.
- Over the past 5 years, BioXcel Therapeutics' Cost of Revenue peaked at $1.2 million during Q3 2024, and registered a low of $9000.0 during Q4 2022.
- Over the past 4 years, BioXcel Therapeutics' median Cost of Revenue value was $62000.0 (recorded in 2024), while the average stood at $273615.4.
- As far as peak fluctuations go, BioXcel Therapeutics' Cost of Revenue skyrocketed by 783333.33% in 2023, and later plummeted by 9905.98% in 2025.
- BioXcel Therapeutics' Cost of Revenue (Quarter) stood at $9000.0 in 2022, then skyrocketed by 7833.33% to $714000.0 in 2023, then rose by 16.53% to $832000.0 in 2024, then plummeted by 98.68% to $11000.0 in 2025.
- Its last three reported values are $11000.0 in Q3 2025, $107000.0 for Q2 2025, and $14000.0 during Q1 2025.